Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: a single-arm phase II trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Pelvic radiotherapy and sexual function in women

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Hyponatremia and metabolic bone disease in patients with epilepsy: A cross-sectional study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Ascorbic acid (AA) has in vivo cytotoxic properties at concentrations that can only be achieved through intravenous (IV) administration in humans. Treatment with intravenous AA is widely and increasingly used in complementary medicine despite a lack of clinical evidence for the efficacy of this treatment.

METHODS: This non-comparative, single-center, phase II trial included patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer (mCRPC) from an outpatient clinic to evaluate the efficacy and safety of IV AA therapy. Patients received weekly infusions of AA (week 1, 5 g; week 2, 30 g; and weeks 3-12, 60 g) followed by efficacy evaluation at 12 weeks. The primary endpoint for efficacy was a 50% reduction in the prostate-specific antigen (PSA) level. The secondary endpoints included changes in health-related quality of life (HRQoL), biomarkers of bone metabolism, inflammation and bone scans. Clinicaltrials.gov identifier: NCT01080352.

RESULTS: Twenty-three patients were enrolled in this study, and 20 completed the efficacy evaluation at 12 weeks. The mean baseline PSA level was 43 µg/L. No patient achieved a 50% PSA reduction; instead, a median increase in PSA of 17 µg/L was recorded at week 12. Among the secondary endpoints, no signs of disease remission were observed. In total, 53 adverse events (AEs) were recorded. Eleven were graded as "serious". Three AEs were directly related to AA, and all of which were related to fluid load.

CONCLUSIONS: Infusion with 60 g of AA did not result in disease remission. This study does not support the use of intravenous AA outside clinical trials.

OriginalsprogEngelsk
TidsskriftTranslational Andrology and Urology
Vol/bind6
Udgave nummer3
Sider (fra-til)517-528
Antal sider12
ISSN2223-4691
DOI
StatusUdgivet - jun. 2017

ID: 51443837